Published in Bioorg Med Chem Lett on December 15, 2003
A zeta potential value determines the aggregate's size of penta-substituted [60]fullerene derivatives in aqueous suspension whereas positive charge is required for toxicity against bacterial cells. J Nanobiotechnology (2015) 1.41
Toxicity of Graphene Shells, Graphene Oxide, and Graphene Oxide Paper Evaluated with Escherichia coli Biotests. Biomed Res Int (2015) 1.39
Cationic fullerenes are effective and selective antimicrobial photosensitizers. Chem Biol (2005) 1.28
Anti-influenza activity of c60 fullerene derivatives. PLoS One (2013) 0.87
Review on the Antimicrobial Properties of Carbon Nanostructures. Materials (Basel) (2017) 0.77
Carbon Nanomaterials as Antibacterial Colloids. Materials (Basel) (2016) 0.76
Suppression of synaptic plasticity by fullerenol in rat hippocampus in vitro. Int J Nanomedicine (2016) 0.75
Synthesis and properties of novel water-soluble fullerene-glycine derivatives as new materials for cancer therapy. J Mater Sci Mater Med (2015) 0.75
Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol (2002) 5.52
Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol (2009) 3.12
Effect on tumor cells of blocking survival response to glucose deprivation. J Natl Cancer Inst (2004) 2.30
High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol (2005) 2.24
Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. J Biol Chem (2004) 2.17
Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res (2003) 2.04
Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J Natl Cancer Inst (2006) 2.00
An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res (2002) 1.82
Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. Br J Haematol (2008) 1.81
Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. III. In vitro and in vivo antitumor activities. J Antibiot (Tokyo) (2004) 1.74
Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. J Immunol (2003) 1.70
Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Res (2005) 1.65
PPARalpha protects proximal tubular cells from acute fatty acid toxicity. J Am Soc Nephrol (2007) 1.62
Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J Biol Chem (2006) 1.55
Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res (2013) 1.52
Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. Cancer Sci (2008) 1.43
Negative regulation of transforming growth factor-beta (TGF-beta) signaling by WW domain-containing protein 1 (WWP1). Oncogene (2004) 1.42
Advances in development of phosphatidylinositol 3-kinase inhibitors. Curr Med Chem (2009) 1.38
Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica (2011) 1.32
Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39. Eur J Cancer (2010) 1.30
ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms. Cancer Sci (2007) 1.30
Interferon-gamma stimulates the expression of galectin-9 in cultured human endothelial cells. J Leukoc Biol (2002) 1.29
Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin Cancer Res (2011) 1.28
Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting. Sci Transl Med (2011) 1.26
p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target. J Natl Cancer Inst (2005) 1.23
Evolutional study on acetylcholine expression. Life Sci (2003) 1.22
Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations. Cancer Res (2010) 1.21
Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb. Clin Cancer Res (2012) 1.17
Regulation of galectin-9 expression and release in Jurkat T cell line cells. Glycobiology (2002) 1.17
Antibacterial activity of dipropofol and related compounds. Biol Pharm Bull (2005) 1.16
Selective eosinophil adhesion to fibroblast via IFN-gamma-induced galectin-9. J Immunol (2002) 1.16
Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer. Clin Cancer Res (2005) 1.15
Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211. J Clin Oncol (2012) 1.15
Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform. Biochem Biophys Res Commun (2003) 1.13
Synthesis and biological relationships of 3',6-substituted 2-phenyl-4-quinolone-3-carboxylic acid derivatives as antimitotic agents. Bioorg Med Chem (2005) 1.13
SKI and MEL1 cooperate to inhibit transforming growth factor-beta signal in gastric cancer cells. J Biol Chem (2008) 1.10
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays. Mol Cancer Ther (2005) 1.10
Galectin-8 modulates neutrophil function via interaction with integrin alphaM. Glycobiology (2003) 1.09
Csk defines the ability of integrin-mediated cell adhesion and migration in human colon cancer cells: implication for a potential role in cancer metastasis. Oncogene (2004) 1.09
ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system. Acta Pharmacol Sin (2010) 1.08
Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int J Cancer (2002) 1.07
Expression of taurine transporter is regulated through the TonE (tonicity-responsive element)/TonEBP (TonE-binding protein) pathway and contributes to cytoprotection in HepG2 cells. Biochem J (2004) 1.07
Leptosins isolated from marine fungus Leptoshaeria species inhibit DNA topoisomerases I and/or II and induce apoptosis by inactivation of Akt/protein kinase B. Cancer Sci (2005) 1.06
Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells. Biol Pharm Bull (2007) 1.05
Platelet size deviation width, platelet large cell ratio, and mean platelet volume have sufficient sensitivity and specificity in the diagnosis of immune thrombocytopenia. Br J Haematol (2005) 1.04
Taurine inhibits apoptosis by preventing formation of the Apaf-1/caspase-9 apoptosome. Am J Physiol Cell Physiol (2004) 1.04
N-cadherin-mediated cell adhesion determines the plasticity for cell alignment in response to mechanical stretch in cultured cardiomyocytes. Biochem Biophys Res Commun (2005) 1.03
Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Haematologica (2008) 1.02
Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor. Eur J Cancer (2009) 1.01
Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest. Biochem Biophys Res Commun (2008) 1.01
Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase. Biol Pharm Bull (2009) 1.01
Why is taurine cytoprotective? Adv Exp Med Biol (2003) 1.01
Galectin-9 ameliorates immune complex-induced arthritis by regulating Fc gamma R expression on macrophages. Clin Immunol (2009) 1.00
Human immunodeficiency virus-reverse transcriptase inhibition and hepatitis C virus RNA-dependent RNA polymerase inhibition activities of fullerene derivatives. Bioorg Med Chem Lett (2005) 1.00
Synthesis and biological evaluation of boronic acid containing cis-stilbenes as apoptotic tubulin polymerization inhibitors. ChemMedChem (2006) 1.00
Activating transcription factor 4 increases the cisplatin resistance of human cancer cell lines. Cancer Res (2003) 0.99
Degradation of NFAT5, a transcriptional regulator of osmotic stress-related genes, is a critical event for doxorubicin-induced cytotoxicity in cardiac myocytes. J Biol Chem (2006) 0.99
Nucleotide sequence variation is frequent in the mitochondrial DNA displacement loop region of individual human tumor cells. Mol Cancer Res (2005) 0.99
LDOC1, a novel MZF-1-interacting protein, induces apoptosis. FEBS Lett (2005) 0.99
Taurine prevents the ischemia-induced apoptosis in cultured neonatal rat cardiomyocytes through Akt/caspase-9 pathway. Biochem Biophys Res Commun (2004) 0.98
N-cadherin signals through Rac1 determine the localization of connexin 43 in cardiac myocytes. J Mol Cell Cardiol (2006) 0.98
PPAR{alpha} attenuates the proinflammatory response in activated mesangial cells. Am J Physiol Renal Physiol (2008) 0.97
In vitro free radical scavenging activity of platinum nanoparticles. Nanotechnology (2009) 0.96
Antiproliferative and antiangiogenic activities of smenospongine, a marine sponge sesquiterpene aminoquinone. Mar Drugs (2011) 0.96
Tea polyphenols regulate nicotinamide adenine dinucleotide phosphate oxidase subunit expression and ameliorate angiotensin II-induced hyperpermeability in endothelial cells. Hypertens Res (2003) 0.95
Rac1 activity is required for cardiac myocyte alignment in response to mechanical stress. Biochem Biophys Res Commun (2006) 0.95
Anticancer mechanisms of YC-1 in human lung cancer cell line, NCI-H226. Biochem Pharmacol (2007) 0.94
Effect of taurine and potential interactions with caffeine on cardiovascular function. Amino Acids (2014) 0.94
Synthesis and preclinical evaluations of 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one monosodium phosphate (CHM-1-P-Na) as a potent antitumor agent. J Med Chem (2010) 0.93
The G protein-coupled receptor T-cell death-associated gene 8 (TDAG8) facilitates tumor development by serving as an extracellular pH sensor. Proc Natl Acad Sci U S A (2010) 0.92
Functional analysis of the carbohydrate recognition domains and a linker peptide of galectin-9 as to eosinophil chemoattractant activity. Glycobiology (2002) 0.92
Regulation of human Fc epsilon RI alpha-chain gene expression by multiple transcription factors. J Immunol (2002) 0.91
Synthesis and pharmacological evaluation of the novel pseudo-symmetrical tamoxifen derivatives as anti-tumor agents. Biochem Pharmacol (2007) 0.91
Reduced sialidase expression in highly metastatic variants of mouse colon adenocarcinoma 26 and retardation of their metastatic ability by sialidase overexpression. Int J Cancer (2002) 0.91
AMF-26, a novel inhibitor of the Golgi system, targeting ADP-ribosylation factor 1 (Arf1) with potential for cancer therapy. J Biol Chem (2011) 0.91
Synthesis of functional proteins by mixing peptide motifs. Chem Biol (2004) 0.91
Proteomics-based identification of biomarkers for predicting sensitivity to a PI3-kinase inhibitor in cancer. Biochem Biophys Res Commun (2006) 0.90
Structural basis for DNA-cleaving activity of resveratrol in the presence of Cu(II). Bioorg Med Chem (2005) 0.90
Triterpene saponins from the roots of Clematis chinensis. J Nat Prod (2004) 0.90
Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study. Cancer Sci (2012) 0.89
Possible inhibitory mechanism of Curcuma drugs on CYP3A4 in 1alpha,25 dihydroxyvitamin D3 treated Caco-2 cells. Int J Pharm (2007) 0.89
Total synthesis of the bicyclic depsipeptide HDAC inhibitors spiruchostatins A and B, 5''-epi-spiruchostatin B, FK228 (FR901228) and preliminary evaluation of their biological activity. Chemistry (2009) 0.89
Potential roles of galectins in myeloid differentiation into three different lineages. J Leukoc Biol (2003) 0.89
JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs. Bioorg Med Chem (2012) 0.89
Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations. Lung Cancer (2010) 0.89
A TLR2 ligand suppresses allergic inflammatory reactions by acting directly on mast cells. Int Arch Allergy Immunol (2009) 0.88
Urukthapelstatin A, a novel cytotoxic substance from marine-derived Mechercharimyces asporophorigenens YM11-542. I. Fermentation, isolation and biological activities. J Antibiot (Tokyo) (2007) 0.88
Phase 1/2 clinical study of dasatinib in Japanese patients with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol (2009) 0.87
Evaluation of action mechanisms of toxic chemicals using JFCR39, a panel of human cancer cell lines. Mol Pharmacol (2007) 0.87
Bacteroides induce higher IgA production than Lactobacillus by increasing activation-induced cytidine deaminase expression in B cells in murine Peyer's patches. Biosci Biotechnol Biochem (2009) 0.87